Want to see HK:2563 full AI Analyst Report?
2563 Stock Chart & Stats
HK$6.36
HK$0.54(3.44%)
At close: 4:00 PM EST
HK$6.36
HK$0.54(3.44%)
Day’s Range― - ―
52-Week RangeHK$2.40 - HK$9.46
Previous CloseN/A
Volume105.40K
Average Volume (3M)22.55K
Market Cap
HK$1.66B
Enterprise ValueHK$843.39
Total Cash (Recent Filing)HK$516.22M
Total Debt (Recent Filing)HK$1.61M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Jul 05, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding389,588,000
10 Day Avg. Volume18,080
30 Day Avg. Volume22,553
Financial Highlights & Ratios
PEG Ratio1.35
Price to Book (P/B)2.41
Price to Sales (P/S)48.10
P/FCF Ratio-10.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginThe exceptionally high gross margin indicates strong product-level economics and leaves substantial revenue available to support operating expenses. If the company can restore growth and control its cost base, this margin profile could provide meaningful operating leverage over the next several quarters.
Very Low LeverageExtremely low leverage limits solvency pressure and reduces the burden of interest or refinancing obligations. This conservative financing structure gives management greater flexibility to address operating challenges and pursue development without the balance-sheet strain associated with heavy borrowing.
Sizable Equity BaseA sizable equity base provides a financial cushion while the company works through losses and business volatility. Although equity has declined, its continued presence alongside minimal debt supports resilience and gives the company more capacity to absorb further operating weakness.
Bears Say
Sharp Revenue DeclineThe steep year-over-year revenue contraction points to an unstable top-line trajectory and weak recent business momentum. Sustained revenue weakness would make it harder to absorb fixed operating costs, preserve scale benefits, and convert the company’s high gross margin into durable earnings.
Persistent Deep LossesLarge recurring operating and net losses show that strong gross margins are currently insufficient to cover the company’s cost base. Without a sustained improvement in revenue or operating discipline, continued losses could erode equity and delay any credible path to profitability.
Ongoing Cash BurnPersistent negative operating and free cash flow means the business is not funding its operations internally. Continued cash burn increases dependence on existing cash or equity funding, limits strategic flexibility, and could make future investment harder if losses remain unresolved.
Beijing Biostar Pharmaceuticals Co., Ltd. Class H News
2563 FAQ
What was Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s price range in the past 12 months?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H lowest stock price was HK$2.40 and its highest was HK$9.46 in the past 12 months.
What is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s market cap?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s market cap is HK$1.66B.
When is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date is Jul 05, 2027 which is in 281 days.
How were Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s earnings last quarter?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H released its earnings results on Aug 26, 2026. The company reported -HK$0.083 earnings per share for the quarter.
Is Beijing Biostar Pharmaceuticals Co., Ltd. Class H overvalued?
According to Wall Street analysts Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s price is currently Overvalued.
Does Beijing Biostar Pharmaceuticals Co., Ltd. Class H pay dividends?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H does not currently pay dividends.
What is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s EPS estimate?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beijing Biostar Pharmaceuticals Co., Ltd. Class H have?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H has 389,588,000 shares outstanding.
What happened to Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s price movement after its last earnings report?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H reported an EPS of -HK$0.083 in its last earnings report. Following the earnings report the stock price went up 3.714%.
Which hedge fund is a major shareholder of Beijing Biostar Pharmaceuticals Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2563
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beijing Biostar Pharmaceuticals Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
Company Description
Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
Beijing Biostar Pharmaceuticals Co., Ltd. Class H (2563) Earnings & Revenues
Technical Analysis
Luye Pharma Group
―
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
―
CANbridge Pharmaceuticals Inc.
―
Fangzhou Inc.
―
Hangzhou Jiuyuan Gene Engineering Co Ltd Class H
―